Alnylam Receives Undisclosed Milestone from Roche Under RNAi Rx Collaboration
January 07, 2010
Alnylam Receives Undisclosed Milestone from Roche Under RNAi Rx Collaboration
The companies first began working together in 2007. Under that agreement, Roche acquired a non-exclusive license to use Alnylam's fundamental RNAi intellectual property to develop therapeutics in oncology, respiratory diseases, metabolic diseases, and certain liver diseases.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In 2011, miRNAs Move Beyond 'Scientific Curiosity' as Big Pharma Externalizes Oligo Drug Development
January 5, 2012 / Gene Silencing News - Former Ribopharma Founders Buy Roche's German RNA Drugs Site to Launch Services Business
December 1, 2011 / Gene Silencing News - Tekmira Touts Advances with Lipid Nanoparticle Technology
March 31, 2011 / Gene Silencing News - Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 6, 2011 / Gene Silencing News - Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 9, 2010 / Gene Silencing News